INTRODUCTION

We wanted to challenge the understanding of duodenal ulcer disease pathophysiology and therapy, along with Selye’s and Szabo’s cysteamine duodenal lesions, as the mainstay in the duodenal ulcer disease model (1-3), which argues against “wound healing therapy” (i.e., duodenal ulcer heals like the skin ulcer does). This challenge was realized using duodenocutaneous fistulas in rats and the parallel therapy, likely related to nitric oxide (NO)-system, the stable pentadecapeptide BPC 157, (4-9) (an anti-ulcer peptide supposed to be novel mediator of Robert’s cytoprotection (as stable in human gastric juice more than 14 days) (4-9), known to heal fistulas (10-12) and skin wounds (13-15), the nitric-oxide synthase (NOS)-substrate L-arginine and/or the NOS-inhibitor L-nitro-arginine methyl ester (L-NAME). Up to now, they were not investigated in parallel, in duodenal ulcers (16, 17), which should be important considering the dual significance of the NO-system (8), and the NO-system’s particular role in skin and gastrointestinal lesions healing (5, 18, 19) as well as fistulas healing (10, 12). Besides, we assume sphincter failure as a hallmark of the ongoing injury, in contrast to some considerations about NO-sphincter relations (20), however, unrelated to injurious conditions (21-23). There, we have to assume the dysfunction of the nitricergic pathway (for instance, excision-immediate heavy loss of endothelium cells from the vascular wall results with less NO-production ability (24)), acting differently on the damaged tissue integrity (10, 25).

In principle, as emphasized before (11), external fistulas form an anomalous connection between skin and gastrointestinal tract.

DUODENOCUTANEOUS FISTULA IN RATS AS A MODEL FOR “WOUND HEALING-THERAPY” IN ULCER HEALING: THE EFFECT OF PENTADECAPETIDE BPC 157, L-NITRO-ARGININE METHYL ESTER AND L-ARGININE

While very rarely reported, duodenocutaneous fistula research might alter the duodenal ulcer disease background and therapy. Our research focused on rat duodenocutaneous fistulas, therapy, stable gastric pentadecapeptide BPC 157, an anti-ulcer peptide that healed other fistulas, nitric oxide synthase-substrate L-arginine, and nitric oxide synthase-inhibitor L-nitro-arginine methyl ester (L-NAME). The hypothesis was, duodenal ulcer-healing, like the skin ulcer, using the successful BPC 157, with nitric oxide-system involvement, the “wound healing-therapy”; to heal the duodenal ulcer, the fistula-model that recently highlighted gastric and skin ulcer healing. Pressure in the lower esophageal and pyloric sphincters was simultaneously assessed. Duodenocutaneous fistula-rats received BPC 157 (10 µg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days. Duodenocutaneous fistula-rats maintained persistent defects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4th day, all fully counteracted in all BPC 157-rats. The BPC 157-rats experienced rapidly improved complete presentation (maximal volume instilled already at 7th day). L-NAME further aggravated the duodenocutaneous fistula-course (mortality at 70% until the 4th day); L-arginine was beneficial (no mortality; however, maximal volume instilled not before 21st day). L-NAME-worsening was counteracted to the control level with the L-arginine effect, and vice versa, while BPC 157 annullled the L-NAME effects (L-NAME + L-arginine; L-NAME + BPC 157; L-NAME + L-arginine + BPC 157 brought below the level of the control). It is likely that duodenocutaneous fistulas, duodenal/skin defect simultaneous healing, reinstated sphincter function, are a new nitric oxide-system related phenomenon. In conclusion, resolving the duodenocutaneous fistulas-healing, nitric oxide-system involvement, should illustrate further wound healing therapy to heal duodenal ulcers.

Key words: stable gastric pentadecapeptide, duodenocutaneous fistula, nitric oxide, wound healing, nitric oxide synthase inhibitor, L-arginine

S. SKORJANEC1, A. KOKOT1, D. DRMIC1, B. RADIC1, M. SEVER1, R. KLICEK1, D. KOLENC2, A. ZENKO2, M. LOVRIC BENČIC2, Z. BELOŠIC HALLE1, A. SITUM1, G. ZIVANOVIĆ POŠILOVIĆ1, S. MASNEC1, J. SURAN1, G. ARALICA1, S. SEIJWERTH1, P. SIKRIRIČ1

DUODENOCUTANEOUS FISTULA IN RATS AS A MODEL FOR “WOUND HEALING-THERAPY” IN ULCER HEALING: THE EFFECT OF PENTADECAPETIDE BPC 157, L-NITRO-ARGININE METHYL ESTER AND L-ARGININE

1Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia; 2Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia; 3Department of Anatomy and Neuroscience, Medical Faculty, J.J Strossmayer University of Osijek, Osijek, Croatia

JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2015, 66, 4, 581-590
www.jpp.krakow.pl


While very rarely reported, duodenocutaneous fistula research might alter the duodenal ulcer disease background and therapy. Our research focused on rat duodenocutaneous fistulas, therapy, stable gastric pentadecapeptide BPC 157, an anti-ulcer peptide that healed other fistulas, nitric oxide synthase-substrate L-arginine, and nitric oxide synthase-inhibitor L-nitro-arginine methyl ester (L-NAME). The hypothesis was, duodenal ulcer-healing, like the skin ulcer, using the successful BPC 157, with nitric oxide-system involvement, the “wound healing-therapy”; to heal the duodenal ulcer, the fistula-model that recently highlighted gastric and skin ulcer healing. Pressure in the lower esophageal and pyloric sphincters was simultaneously assessed. Duodenocutaneous fistula-rats received BPC 157 (10 µg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days. Duodenocutaneous fistula-rats maintained persistent defects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4th day, all fully counteracted in all BPC 157-rats. The BPC 157-rats experienced rapidly improved complete presentation (maximal volume instilled already at 7th day). L-NAME further aggravated the duodenocutaneous fistula-course (mortality at 70% until the 4th day); L-arginine was beneficial (no mortality; however, maximal volume instilled not before 21st day). L-NAME-worsening was counteracted to the control level with the L-arginine effect, and vice versa, while BPC 157 annullled the L-NAME effects (L-NAME + L-arginine; L-NAME + BPC 157; L-NAME + L-arginine + BPC 157 brought below the level of the control). It is likely that duodenocutaneous fistulas, duodenal/skin defect simultaneous healing, reinstated sphincter function, are a new nitric oxide-system related phenomenon. In conclusion, resolving the duodenocutaneous fistulas-healing, nitric oxide-system involvement, should illustrate further wound healing therapy to heal duodenal ulcers.

Key words: stable gastric pentadecapeptide, duodenocutaneous fistula, nitric oxide, wound healing, nitric oxide synthase inhibitor, L-arginine
that provides a direct and unusual contact between these
different, normally separated, tissues, thereby resulting in special
new circumstances and healing difficulties, and a failure of
regular healing that is otherwise not present. In particular, this
fistula is the only new healing model that practically combines
the potentially different processes that might occur
simultaneously at the skin and other gastrointestinal wound, and
provide insight into the special healing effects of agents under
investigation (i.e., the skin wound healing effect could contribute to
the healing of gastrointestinal ulcer and vice versa, while
spontaneous healing is lacking). Fistula closing may therefore be
a useful self-controlling system for both skin and gastrointestinal
defect healing (10-12). We should emphasize that BPC 157 (as
described (4-9)) avoids all the practical pitfalls for fistula healing
using peptidergic growth factors (i.e., standard growth factors
would hardly combine skin and gastrointestinal ulcer healing due
to the different way of administration and drug delivery to
gastrointestinal ulcer and skin ulcer (26, 27)). Of note, BPC 157
is always given alone, and thereby may act directly, always using
the same dosage range. This is different from the commonly used
standard growth factors (i.e., EGF) which are given with carriers
(4-9) and require special delivery systems for skin healing (but
not for gastrointestinal ulcer healing) (26, 27).
Therefore, in view of the current reports (4-12), we could
envisage a duodenocutaneous fistula model with the BPC 157
application, using the same dose, with skin healing as part of the
corresponding healing of gastrointestinal, and in particular,
duodenal ulcer healing.

Once the rat duodenocutaneous fistulas are resolved, the
consequences thereof could be over the present insignificance of
duodenocutaneous fistulas (i.e., a very rare complication of
duodenal ulcer disease, most often felt to occur following ulcer
surgery (28), but experimentally not investigated), or the
possibility of the skin wound that would constitute an entirely
different type of the tissue than the gut mucosa and subepithelial
tissues unreliable for common therapy.

Finally, in view of several recent reports (4-12), orderly
development of rat fistulas (made by direct sutured anastomosis
between the two structures (10-12)), fistulas suddenly
developed, relentlessly progressive (even for a period of several
weeks or more, if not lethal) (10-12) might accordingly
reproduce the phenomenon of poor fistulas healing which may
occur during spontaneous disease.

Thus, we could suggest that the resolved rat
duodenocutaneous fistulas, the newly definable course of the
duodenal ulcer (that we initially controlled) as like that of the skin
ulcer (that also we initially controlled). The anatomic (duodenal
defect at ventral side, 2 mm from pylorus) and clinical identity
(poor and long lasting healing) of what we now call
duodenocutaneous fistula would ascertain a complicated duodenal
and skin ulcer and their implemented simultaneous healing (with
a suited therapy) or the persistent partial (one defect left) or
complete (both defects left) failure (without adequate therapy).

This mandates that a successful BPC 157 effect (previously,
without acting on gastric acid secretion (4-9), it healed the
cysteamine pathology (29-33)), should be the synchronized
healing of the different tissues, as shown with the healing of the
gastrocutaneous, esophagocutaneous, and colocutaneous fistulas,
also through the NO-system (10-12), and also interacting with
NO-agents in different models and species (10, 12, 25, 34-40).
Likely, this could be the extended NO-system involvement (with
the gastric lesions, despite inconsistencies, L-arginine has a
beneficial effect, while L-NAMe has an ulcerogenic effect (8,
36)), they were far less investigated in duodenal lesions (16, 17).

Indeed, BPC 157 has a particular potential to act as combining
therapy in the whole gastrointestinal tract (5, 6) (esophageal (41-
43), gastric (31, 36, 44), duodenal (29-33) and colitis lesions’
counteraction (12)), and the ameliorated course after the
experimental creation of the more complex conditions and
complications (44-46) in rats, including those induced by various
NSAIDs (47-49). Besides, BPC 157 has particular effects on the
wound-healing process in different tissues (50-55), including
blood vessels (9, 30, 39, 52-54) and in particular burn wounds (13-
15). This is most likely due to the stimulation of the early growth
response-1 (egr-1) gene and its co-repressor nerve growth factor
1-A binding protein-2 (nAb2), which are also responsible for
cytokine and growth factor generation and thereby, early
extracellular matrix (collagen) and blood vessel formation (55).
The others correlated the BPC 157 beneficial effects with the
activation of a cellular focal adhesion kinase (FAK)-paxillin signal
pathway and subsequently demonstrated that BPC 157, dose-
and time-dependently, increased the expression of growth hormone
receptor, Janus kinase 2 (JAK-2), the downstream signal pathway
of growth hormone receptor (56, 57).

Thus, responding to this novel model challenge with rat
duodenocutaneous fistula, we suggest an additional particular
wound healing background (13-15, 54, 57, 58) for fistula healing
(10-12) and potential agent’s efficacy.

For practical purposes, the stable gastric pentadecapeptide
BPC 157 was given daily, intraperitoneally or perorally, in drinking
water, using the previous efficacious regimens as in the other
external fistulas healing trials (10-12). In addition, these effects
(stable gastric pentadecapeptide BPC 157, along with NOS-
blockade, L-NAMe, and NOS-substrate L-arginine application
(5)), might better clarify the healing of duodenal and skin defects
and duodenocutaneous fistulas, and find possible simultaneous or
separate healing, as a new NO-system related phenomenon.

MATERIALS AND METHODS

Animals

Wistar Albino male rats (200 g b.w.) were randomly
assigned to the experiments (10 animals, at least, per each
experimental group and interval), all of which were approved by
the Local Ethics Committee. Furthermore, all experiments were
carried out under blind protocol and the effect was assessed by
examiners who were completely unaware of the given protocol.

Drugs

Pentadecapeptide BPC 157 (GEPPPGPKADDAGL, M.W.
1419), (Diagen, Ljubljana, Slovenia) dissolved in saline, was
used in all experiments. The peptide, BPC 157, is part of the
sequence of human gastric juice protein, BPC, and is freely
soluble in water at pH 7.0 and saline. It was prepared as
described previously with 99% high pressure liquid
chromatography (HPLC) purity, expressing 1-des-Gly peptide as
an impurity (4-12, 30). L-NAMe (Sigma, USA) and L-arginine
(Sigma, USA) were accordingly used.

Procedure

Using a previous procedure, the direct anastomosis between
the two structures (10-12), in deeply anaesthetized rats. The
purpose of surgery was the creation of a duodenocutaneous
fistula (2 mm diameter duodenum (at ventral side, 2 mm from
pylorus) and 3 mm diameter skin defect at the proximal third
part of medial incision, where a precise caliper was used to
verify the initial size of the defect), as described before (11).
Direct anastomosis between the two structures, duodenum and
skin, was performed and sutured (Vycril 2-0, Johnson &
Johnson) to form a channel.
Experimental protocol

Using a previous procedure and regimens (10-12), BPC 157 was given perorally, in drinking water (10 µg/kg, 10 ng/kg, i.e., 0.16 µg/mL, 0.16 ng/mL, 12 mL/rat/day) till sacrifice, or alternatively, 10 µg/kg, 10 ng/kg intraperitoneally, first application at 30 min after surgery, last at 24 hours before sacrifice. L-NAME (5 mg/kg intraperitoneally) and/or L-arginine (100 mg/kg intraperitoneally) were given alone or together, first application at 30 min after surgery, last at 24 hours before sacrifice. BPC 157 10 µg/kg, intraperitoneally or perorally, was given with L-NAME (5 mg/kg intraperitoneally) before sacrifice. BPC 157 10 µg/kg, intraperitoneally or (5.0 mL/kg intraperitoneally) or water only.

The assessment was at day 1, 2, 3, 7, 14 and 21 as follows.

Duodenum defect, skin defect, fistula assessment

A precise caliper was used to verify the final size of the defect. The largest diameter of the skin or duodenal defect was assessed (mm), photographed and further verified using the program ISSA (VAMSTEC Software Company, Zagreb, Croatia), and the tissue processed for further microscopic analysis (10-12).

To assess fistula leakage, a separate group of animals received a volume of water intragastrically (1 ml/6 s), either to leaking induction, or to a maximal volume of 20 ml (10-12). In this case, if leakage did not occur after 5 min, the fistula was considered functionally closed.

Lower esophageal sphincter pressure assessment and pyloric sphincter pressure assessment

As described before (10, 25, 41-43), in all rats, manometrical evaluation (cm H₂O) was performed with a water manometer connected to the drainage port of the Foley catheter as described (the values of 68 – 76 cm H₂O for lower esophageal sphincter, and 68 – 74 cm H₂O for pyloric sphincter, were considered to be normal as determined before (10, 25, 41-43)). The proximal side of the esophageal, or distal side of the duodenal incision, was ligated to prevent regurgitation.

Mortality assessment

Mortality rate (%) was assessed throughout the study (45).

Statistical analyses

Statistical analysis was performed by a non-parametric Kruskal-Wallis ANOVA, and subsequent Mann-Whitney U-test, to compare groups. Fisher’s exact probability test for mortality rate assessment was used. Values of P < 0.05 were considered statistically significant.

RESULTS

We demonstrated a consistent counteracting beneficial effect in all BPC 157 rats (i.e., given perorally (in drinking water) or intraperitoneally), on its own, and with NOS-blockade (L-NAME) and/or NOS-substrate (L-arginine). A simultaneous effect was demonstrated on the closure of skin, duodenal, fistula defects; healing occurred macro/microscopically, biomechanically, and functionally, as well as reinstating sphincter functions; no mortality. On the other hand, an opposite persistent lesion course was portrayed in controls (persistent lesions, leaking, failure biomechanically and functionally, low pressure within sphincters, and mortality). There was a counteracting beneficial effect of L-arginine, and an opposite, additionally aggravating one of L-NAME, with their mutual counteraction. Thus, in rats’ duodenocutaneous fistulas the

<table>
<thead>
<tr>
<th>Medication (/kg):</th>
<th>Mucosal defect after formation of duodenocutaneous fistula (days) in rat (largest diameter, means ± S.D., mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Saline 5 ml IP</td>
<td>2.0 ± 0.2</td>
</tr>
<tr>
<td>Drinking water12 ml/day/rat</td>
<td>2.0 ± 0.2</td>
</tr>
<tr>
<td>BPC 157 10 ng IP</td>
<td>2.0 ± 0.3</td>
</tr>
<tr>
<td>BPC 157 10 ng PO</td>
<td>2.0 ± 0.2</td>
</tr>
<tr>
<td>BPC 157 10 µg IP</td>
<td>2.0 ± 0.1</td>
</tr>
<tr>
<td>BPC 157 10 µg PO</td>
<td>2.0 ± 0.2</td>
</tr>
<tr>
<td>L-NAME 5 mg IP</td>
<td>2.0 ± 0.2</td>
</tr>
<tr>
<td>L-arginine 100 mg IP</td>
<td>2.0 ± 0.2</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + BPC 157 10 µg IP</td>
<td>2.0 ± 0.3</td>
</tr>
<tr>
<td>L-arginine 100 mg IP + BPC 157 10 µg IP</td>
<td>2.0 ± 0.1</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + L-arginine 100 mg IP + BPC 157 10 µg IP</td>
<td>2.0 ± 0.2</td>
</tr>
</tbody>
</table>

*P < 0.05, at least vs. corresponding control.
duodenal and the skin defect follow the same pattern of healing (*P < 0.05, at least vs. corresponding control).

<table>
<thead>
<tr>
<th>Medication (µg/kg):</th>
<th>Skin defect after formation of duodenocutaneous fistula (days) in rat (largest diameter, mean ± S.D., mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Saline (5 ml IP)</td>
<td>3.0 ±  0.3</td>
</tr>
<tr>
<td>Drinking water (12 ml/day/rat)</td>
<td>3.0 ±  0.4</td>
</tr>
<tr>
<td>BPC 157 10 ng IP</td>
<td>3.0 ±  0.3</td>
</tr>
<tr>
<td>BPC 157 10 ng PO</td>
<td>3.0 ±  0.4</td>
</tr>
<tr>
<td>BPC 157 10 µg IP</td>
<td>3.0 ±  0.4</td>
</tr>
<tr>
<td>BPC 157 10 µg PO</td>
<td>3.0 ±  0.4</td>
</tr>
<tr>
<td>L-NAME 5 mg IP</td>
<td>3.0 ±  0.3</td>
</tr>
<tr>
<td>L-arginine 100 mg IP</td>
<td>3.0 ±  0.4</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + BPC 157 10 µg IP</td>
<td>3.0 ±  0.3</td>
</tr>
<tr>
<td>L-arginine 100 mg IP + BPC 157 10 µg IP</td>
<td>3.0 ±  0.3</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + L-arginine 100 mg IP + BPC 157 10 µg IP</td>
<td>3.0 ±  0.4</td>
</tr>
</tbody>
</table>

As mentioned, if not treated otherwise, duodenocutaneous fistulas exhibited poor healing (Tables 1–5, Fig. 1), with persistence of defects (Tables 1 and 2), continuous fistula leakage (Table 3), sphincter failure (Table 4) and significant mortality rate (Table 5). BPC 157 given perorally or intraperitoneally, in µg- and ng-regimens, rapidly improved complete presentation (Tables 1–5, Fig. 1) (maximal volume instilled already at 7th day (Table 3)). Considering the NO-agents effects, and NO-system involvement, L-arginine was also beneficial in all aspects (no mortality; however, maximal volume instilled not before 21st day) (Tables 1–5) while L-NAME application further aggravated entire duodenocutaneous fistulas course (Tables 1–5), with even higher mortality rate (Table 5). Considering the possible mutual interaction, L-arginine brings down aggravation by NOS-blockade with L-NAME to the control levels. Interestingly, L-NAME appears to be more sensitive to BPC 157 application providing that BPC 157 more than nullifies the effect of L-NAME (i.e., L-NAME + BPC 157; L-NAME + L-arginine + BPC 157 markedly improved over control values) (Tables 1–5). Thus, BPC 157 effects appear to be stronger than those of L-arginine, and this is illustrated in the earlier biomechanical improvement, in the early interval, where BPC 157 + L-arginine rats achieved the maximal volume.

Generally, in duodenocutaneous fistula-rats (Fig. 1) the microscopic presentation (i.e., severe necrosis along the fistula wall, including a large necrotic area of superficial epithelium and...
Table 4. Pressure (means ± SD, cm H₂O) in lower esophageal sphincter and pyloric sphincter throughout the days after duodenocutaneous fistula formation in controls – saline 5 ml/kg intraperitoneally once daily, drinking water only (12 ml/day/rat), BPC 157 – 10 µg/kg or 10 ng/kg, given intraperitoneally, once daily or perorally, in drinking water (0.16 µg/ml or 0.16 ng/ml), L-NAME – 5 mg/kg intraperitoneally, once daily, L-arginine – 100 mg/kg intraperitoneally, once daily, (given alone or together), treated rats.

<table>
<thead>
<tr>
<th>Medication (/kg): Intraperitoneally (IP) - once daily; Perorally (PO) – in drinking water</th>
<th>Sphincters: Lower esophageal sphincter</th>
<th>Pyloric sphincter</th>
<th>Pressure (means ± S.D., cm H₂O) in lower esophageal and pyloric sphincter after formation of duodenocutaneous fistula (days) in rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline 5 ml IP</td>
<td>Lower esophageal sphincter</td>
<td>46.5 ± 2.2</td>
<td>46.7 ± 2.3</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>50.0 ± 4.3</td>
<td>50.0 ± 5.2</td>
</tr>
<tr>
<td>Drinking water 12 ml/day/rat</td>
<td>Lower esophageal sphincter</td>
<td>46.2 ± 2.2</td>
<td>46.0 ± 2.5</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>50.0 ± 12.6</td>
<td>51.7 ± 2.3</td>
</tr>
<tr>
<td>BPC 157 10 ng IP</td>
<td>Lower esophageal sphincter</td>
<td>63.6 ± 3.6*</td>
<td>64.7 ± 3.5*</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>55.7 ± 2.8*</td>
<td>55.6 ± 3.2*</td>
</tr>
<tr>
<td>BPC 157 10 ng PO</td>
<td>Lower esophageal sphincter</td>
<td>65.4 ± 3.2*</td>
<td>64.5 ± 2.7*</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>55.7 ± 2.7*</td>
<td>55.7 ± 3.5*</td>
</tr>
<tr>
<td>BPC 157 10 µg IP</td>
<td>Lower esophageal sphincter</td>
<td>64.0 ± 2.7*</td>
<td>64.5 ± 3.7*</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>56.3 ± 3.1*</td>
<td>55.0 ± 3.6*</td>
</tr>
<tr>
<td>BPC 157 10 µg PO</td>
<td>Lower esophageal sphincter</td>
<td>64.4 ± 2.5*</td>
<td>63.4 ± 3.4*</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>55.6 ± 2.4*</td>
<td>55.4 ± 3.6*</td>
</tr>
<tr>
<td>L-NAME 5 mg IP</td>
<td>Lower esophageal sphincter</td>
<td>39.3 ± 2.2*</td>
<td>39.6 ± 2.6*</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>44.4 ± 2.8*</td>
<td>44.4 ± 2.7*</td>
</tr>
<tr>
<td>L-arginine 100 mg IP</td>
<td>Lower esophageal sphincter</td>
<td>60.6 ± 2.9*</td>
<td>60.1 ± 3.8*</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>51.8 ± 2.9*</td>
<td>51.1 ± 3.4*</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + BPC 157 10 µg IP</td>
<td>Lower esophageal sphincter</td>
<td>64.6 ± 3.1*</td>
<td>64.6 ± 3.5*</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>55.9 ± 3.4*</td>
<td>55.7 ± 3.6*</td>
</tr>
<tr>
<td>L-arginine 100 mg IP + BPC 157 10 µg IP</td>
<td>Lower esophageal sphincter</td>
<td>64.8 ± 2.3*</td>
<td>64.6 ± 3.7*</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>55.6 ± 3.7*</td>
<td>55.7 ± 2.6*</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + L-arginine 100 mg IP</td>
<td>Lower esophageal sphincter</td>
<td>45.6 ± 2.2</td>
<td>45.8 ± 2.8</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>51.7 ± 3.4</td>
<td>51.3 ± 2.7</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + L-arginine 100 mg IP + BPC 157 10 µg IP</td>
<td>Lower esophageal sphincter</td>
<td>64.3 ± 3.6*</td>
<td>64.3 ± 4.0*</td>
</tr>
<tr>
<td></td>
<td>Pyloric sphincter</td>
<td>55.5 ± 3.4*</td>
<td>55.4 ± 3.6*</td>
</tr>
</tbody>
</table>

*P<0.05, at least vs. corresponding control.

Table 5. Mortality rate (%) after duodenocutaneous fistula formation in controls – saline 5 ml/kg intraperitoneally once daily, drinking water only (12 ml/day/rat), BPC 157 – 10 µg/kg or 10 ng/kg, given intraperitoneally, once daily or perorally, in drinking water (0.16 µg/ml or 0.16 ng/ml), L-NAME – 5 mg/kg intraperitoneally, once daily, L-arginine – 100 mg/kg intraperitoneally, once daily (given alone or together) treated rats.

<table>
<thead>
<tr>
<th>Medication (/kg): Intraperitoneally (IP) - once daily; Perorally (PO) – in drinking water</th>
<th>Mortality rate (%) after duodenocutaneous fistula formation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline 5 ml IP</td>
<td>30</td>
</tr>
<tr>
<td>Drinking water 12 ml/day/rat</td>
<td>30</td>
</tr>
<tr>
<td>BPC 157 10 ng IP</td>
<td>0*</td>
</tr>
<tr>
<td>BPC 157 10 ng PO</td>
<td>0*</td>
</tr>
<tr>
<td>BPC 157 10 µg IP</td>
<td>0*</td>
</tr>
<tr>
<td>BPC 157 10 µg PO</td>
<td>0*</td>
</tr>
<tr>
<td>L-NAME 5 mg IP</td>
<td>50*</td>
</tr>
<tr>
<td>L-arginine 100 mg IP</td>
<td>0*</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + BPC 157 10 µg IP</td>
<td>0*</td>
</tr>
<tr>
<td>L-arginine 100 mg IP + BPC 157 10 µg IP</td>
<td>0*</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + L-arginine 100 mg IP</td>
<td>30</td>
</tr>
<tr>
<td>L-NAME 5 mg IP + L-arginine 100 mg IP + BPC 157 10 µg IP</td>
<td>0*</td>
</tr>
</tbody>
</table>

*P<0.05, at least vs. corresponding control.
a broad band of necrotic subcutaneous tissue and muscle after 3 days, fistulous channel walled with granulation tissue after 14 days) followed the described macroscopical healing and previous course of gastrocutaneous fistula-rats (11) (initially, in animals treated with BPC 157, the edema was less pronounced, the superficial epithelium surrounding the defect was practically intact, and the defect was closed by crust, and after 14 days, unlike in the controls, the treated animals showed poor granulation tissue formation and prominent regeneration of subcutaneous muscle fibers) (11).

DISCUSSION

With rats’ duodenocutaneous fistula, the anti-ulcer peptide stable gastric pentadecapeptide BPC 157 (4-12), L-arginine and L-NAME, we considered the “wound healing therapy” notion, versus the conventional understanding of duodenal disease and therapy and the mainstream cysteamine duodenal ulcer model (1-3).

We demonstrated that the rats’ duodenocutaneous fistula healing model, methodologically and therapeutically (BPC 157, L-arginine), strongly combines the healing and therapy of the duodenal and skin defects, NO-system involvement (i.e., counteraction of L-NAME (as harmful effect of NOS-blockade)). Thus, we revealed the essential healing commonality between the BPC 157, L-arginine, L-NAME and NO-system (10, 12); we assumed, due to the injurious tissue loss (24), initial NO-system negative dysfunction that had been manipulated by BPC 157, L-arginine and L-NAME application manipulating in both ways, before tissue injury NO-essential background improved or further aggravated.

Furthermore, in methodology, the controlled (dis)advantages (the uniformly formed defects of the skin and duodenum, then, the persistent lesions, leaking, failure biomechanical and functional, low pressure within sphincters, a long-standing course), causally related, explain that in rat duodenocutaneous fistulas more lesions lead to less sphincter pressure (10, 25, 41-43). Therefore, L-NAME further decreased pressure and L-arginine increased pressure, depending on their negative or positive healing effect. These are in accordance with the effects noted in the esophagocutaneous fistulas- or hyperkalemic-sphincter dysfunction (10, 25) and the obtained sphincters’ interrelation (i.e., the failure of the pyloric sphincter induced the failure of the lower esophageal sphincter (41-43)). Thus, these are in seeming contrast to some considerations about NO-sphincter relations (20-23), providing the dysfunction of the nitric pathway differently acting at the damaged tissue integrity (and obviously prevailed and different from those of NO-esophageal sphincter relaxation (20), obtained in intact dogs (21) or ferrets (22), or muscle strips (23)).

Likely, this NO-system negative dysfunction could be a submaximal one as suggested before (36); since it could be clearly improved (BPC 157, L-arginine) while more hardly aggravated by an additional NOS-blockade (note, L-NAME administration effect is also not significantly different than that of saline control and drinking water at some of respective times). Commonly, BPC 157 counteracted L-NAME better than L-arginine did (8, 10, 12, 25, 34-40), (L-NAME-worsening was counteracted with the L-arginine effect and vice versa (L-NAME + L-arginine brought to the level of the control), while BPC 157 more than negated the L-NAME-worsening (L-NAME + L-arginine + BPC 157; L-NAME + L-arginine +
BPC 157 brought below the level of the control), and accordingly, BPC 157 induces NO-release from gastric mucosa supernatant, like L-arginine, but also in conditions where L-arginine is not working (36).

Consequently, the accurate attribution of the obtained peptide effects, particularly for skin defect healing (where unlike uncertain healing attribution of other peptides which are given with carriers (4-9), BPC 157 is given alone and thereby acts directly), the therapeutic success of BPC 157 over the external fistulas model (10-12) and now in duodenocutaneous fistulas further emphasized the real healing congruence of the skin healing and other gastrointestinal tissues healing. For the healing congruence of both defects, it might be possible that the skin healing methodologically resolves the therapy phenomenon in other gastrointestinal tissues or the skin healing was affected by the healing of any part of the gastrointestinal tract that was connected to the skin. Using the same dose range, BPC 157 achieves the requested healing congruence. Illustratively, BPC 157 had accelerated the healing of severe burns, topicaliy as a cream, or systemically (13-15); BPC 157 had counteracted the severe healing impairment otherwise induced with systemic corticosteroid application (13-15), or allooxan-hyperglycemia (58), overpowered the skin wound healing of the corresponding standard agents (i.e., becaplermin, recombinant human platelet-derived growth factor homodimer of B chains, PDGF-BB; silver sulfadiazine cream) (13-15, 55, 58, 59). In the used dose range this correlate with the counteraction of the esophageal (41-43), gastric (31, 36, 44), duodenal (29-33) and colonic mucosal lesions (12), mitigated andameliorated the course after an experimental creation of the more complex conditions and complications in rats (44-46), and counteracted complex pathology induced by various NSAIDs (47-49). In continuation, this correlates with the healing of created external fistulas (10-12), simultaneous healing of the esophageal, gastric, colonic and skin defects (10-12), and now also, the duodenal defect. Thus, considering the effectiveness after peroral administration, it may be possible that this original anti-ulcer peptide, stable and present in human gastric juice, supposed to maintain mucosal integrity (4-9, 29), BPC 157 is claimed to be a novel mediator of Robert’s cytoprotection (4), may also benefit the skin part of the fistula defect and exert there its beneficial effect. It may be, considering the effectiveness of BPC 157 after intraperitoneal administration, that these are the NO mediating the skin C-fiber reflexes, that mediate skin vasodilatation (60), providing that BPC 157 maintains C-fibres integrity in both neonatal and adults rats that received capsaicin (61).

In this, the practical peptidergic activity is seen by the fact that the peroral (in drinking water) application corresponds to that of the parenteral administration (4-9, 29). Likely important for the fistula’s healing as well, is the particular cytoprotective background (4). More advanced cytoprotective effects for more tissue healing show it to be a particular wound-healing mediator as well (4, 62), and also supported by advanced healing of severe skin wounds (13-15). Using H-labelled pentadecapeptide BPC 157, t/2 was 66 h and 69 h in male and female rats after single oral administration (4-9). In addition, pentadecapeptide BPC 157’s beneficial effect (both in wound and mucosa healing) involves (4-9) reduction of the inflammatory cell numbers, leukotriene B4 (LTB4), thromboxane B2 (TXB2), and myeloperoxidase (MPO) levels in the serum and inflamed tissues (63, 64), and it also increases the macrophage activity (65).

Finally, although this was not especially investigated in the present study, whether this is a receptor-mediated action (57) or not (further studies are required to finalize all these findings (4-9)), they have to be specially related to its molecular effects (55-57). For instance, prominently stimulated expression of the egf-1 gene includes cytokine and growth factor generation, and early extracellular matrix (collagen) formation, and blood vessel function and its repressor naB2 (55), very likely provides a particular feedback-process consistently responsible for the simultaneous healing of two different tissues and fistulas healing (10-12). For example, in duodenal ulcers, the increase in the expression of egf-1 is followed by upregulation of angiogenic growth factors (e.g., VEGF, bFGF, PDGF) (66).

Of note, these additional healing mechanisms of BPC 157, besides those with NO-system (8), show that advanced healing (and collagen) processes (55) fairly reflect the biomechanical improvement (13-15, 45, 46), and vice versa. Therefore, the biomechanical improvement in all BPC 157-rats sustained the markedly advanced volume challenge before leakage, quickly progressing until the successful instillation of the maximal volume, which was achieved already at very early intervals. This indicates the rapidly salvaged fistulas and the advanced healing processes in all BPC 157-rats over the completely failed healing and the consequently small amount of volume that could be sustained in the controls. Also, the advanced biomechanical healing was common in various wounds (13-15, 50, 51, 59), fistulas (10-12), and revealed in the remaining intestine function recovery (45, 46), in BPC 157-studies. Also, based on the observed L-arginine (maximal volume sustained quite later, only at the latest interval; note that maximal volume was achieved earlier in BPC 157 + L-arginine-rats and BPC 157 + L-arginine + L-NAME-rats) and L-NAME effects, these occurrences are obviously related to the NO-system as well.

BPC 157 also has a strong direct angiogenic healing potential (13-15, 50-52, 59) (a particular one since it is present along with the healing processes in hypocellular and hypovascular tissues (13-15, 50-52, 59), but not in vitro conditions (52)). The direct endothelium protection (4, 8, 31), could partly explain its increased influence on the NO-system (8), with a counteracted overexpression of endothelin (38), (note, endothelin has potent ulcerogenic and vasocostrctor actions in the stomach (67), counteraction of the effects of NOS-inhibitors and NO-precursor (8, 10, 12, 25, 34-40), effects which are seen in particular with external fistula healing (10, 12).

Besides, considering the complexity of the described healing, we should assume that additional mechanisms might be also involved (68, 69).

In conclusion, this study revealed the success of the stable gastric pentadecapeptide, BPC 157, in the therapy of duodenocutaneous fistulas in rats, in a well-controlled model equalizing duodenal and skin ulcer healing, with sphincter function reinstated. It has also shown a likely practical, cytoprotective significant effect, in duodenal ulcer and disease, applicable as a further wound healing therapy in fistulas along with the beneficial effect on other fistula healing (10-12) that should be more than experimentally relevant providing its initial use in the ulcerative colitis trials and it’s very safe profile (4-9, 29).

Summarizing, BPC 157, given perorally, or parenterally, promptly improved healing of both duodenal and skin lesions and mediated fistula closing (macro-microscopically, and functionally, with no fistula leakage upon application of the maximal water volume, and reinstated the sphincter function). This effect was shared by L-arginine, with an opposite effect seen by L-NAME, thereby portraying NO-system involvement in the healing of duodenal and skin defects, duodenocutaneous fistula closing and reinstated sphincter functions. Hopefully, by resolving the duodenocutaneous fistula-healing, and NO-system involvement, this should illustrate a further wound healing therapy to heal duodenal ulcers.

This article is based on Authors presentations at the 1st Global Gastrointestinal Club of Experimental Biology/IUPHAR GI Section of ASPET “The Best of my Research: The Last 10 Years” meeting organized in Boston 2013 by Prof. Sandor.
Szabo, University of California, Irvine and GI Section VA Medical Center, Long Beach, California USA.

Conflict of interests: None declared.

REFERENCES


Received: January 11, 2014
Accepted: May 8, 2015

Author’s address: Prof. Predrag Sikiric, Department of Pharmacology, Medical Faculty, University of Zagreb, 11 Salata Street, P.O. Box 916, 1000 Zagreb, Croatia
E-mail: sikiric@mef.hr